

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patentee: Brown *et al.*

Patent No.: 7,189,712

Issued: March 13, 2007

Serial No.: 10/530,810

For: 1,3-OXAZOLE COMPOUNDS FOR THE TREATMENT OF CANCER

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 CFR § 1.322 and 1.323

Mail Stop Post Issue
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed please find a certificate of correction in connection with the above-identified patent. It is respectfully requested that a Certificate of Correction be issued for the above-identified patent, in accordance with 37 C.F.R. § 1.322 and 1.323.

The patentees request correction of the following errors, which were made by the Patent Office and introduced at the time of publication:

Col. 25, line 38, the term "he" should be --the--.

Claim 1, Col. 147, line 19, the term "--(Z)_g" should be --(Z)_q--.

Claim 1, Col. 147, line 20, the term "--(Z)_g" should be --(Z)_q--.

Claim 2, Col. 149, line 35, the term "1,3-oxazol-" should be --1,3-oxazol-2-amine--.

Claim 2, Col. 149, after line 35 and before line 36, the term "5-(4-fluorophenyl)-N-[2-methoxy-5-(thiomorpholin-4-ylsulfonyl)phenyl]-1,3-oxazol-2-amine".

(2) The patentees also request correction of the following error which was a result of the patentees' mistake. Patentee's error occurred in good faith and correction thereof does not involve such changes in the patent as would constitute new matter or would require re-examination. Such correction follows:

Col. 3, line 39, the term "C₁.C₂-halalkoxy," should be -C₁.C₂-haloalkoxy-.

Col. 3, line 52, the term "C₁.C₂-halalkoxy," should be deleted.

Col. 4, line 66, the term "C₁.C₂-halalkoxy," should be -C₁.C₂-haloalkoxy-.

Col. 5, lines 23-24, the term "C₁.C₂-halalkoxy," should be deleted.

Col. 5, line 66, the term "C₁.C₂-halalkoxy," should be -C₁.C₂-haloalkoxy-.

Col. 6, line 10, the term "C₁.C₂-halalkoxy," should be deleted.

Col. 12, line 23, the term "C₁.C₂" should be deleted.

Claim 1, Col. 146, line 64, the term "C₁.C₂-halalkoxy," should be -C₁.C₂-haloalkoxy-.

Claim 1, Col. 147, line 7, the term "C₁.C₂-halalkoxy," should be deleted.

The Certificate of Correction corrects these errors.

The mistakes appearing in the patent are set forth on the Certificate of Correction enclosed herewith, with an additional copy thereof.

Please charge any shortage in the fees, or credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,


John L. Lemanowicz
Registration No. 37,380
Attorney for Patentee

Dated: 3/11/2008
GlaxoSmithKline
Corporate Intellectual Property Dept.
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1467
Facsimile: (919) 483-7988

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,189,712
 DATED : 3/13/07
 INVENTOR(S) : Brown et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 25, line 38, delete "he" and insert therefor --the--.

Claim 1, Col. 147, line 19, delete "--(Z)_g" and insert therefor --(Z)_q--.

Claim 1, Col. 147, line 20, delete "--(Z)_g" and insert therefor --(Z)_q--.

Claim 2, Col. 149, line 35, delete "1,3-oxazol-" and insert therefor --1,3-oxazol-2-amine--.

Claim 2, Col. 149, after line 35 and before line 36, the term "5-(4-fluorophenyl)-N-[2-methoxy-5-(thiomorpholin-4-ylsulfonyl)phenyl]-1,3-oxazol-2-amine".

Col. 3, line 39, delete "C₁.C₂-halalkoxy," and insert therefor --C₁.C₂-haloalkoxy--.

Col. 3, line 52, delete "C₁.C₂-halalkoxy,".

Col. 4, line 66, delete "C₁.C₂-halalkoxy," and insert therefor --C₁.C₂-haloalkoxy--.

Col. 5, lines 23-24, delete "C₁.C₂-halalkoxy,".

Col. 5, line 66, delete "C₁.C₂-halalkoxy," and insert therefor --C₁.C₂-haloalkoxy--.

Col. 6, line 10, delete "C₁.C₂-halalkoxy,".

Col. 12, line 23, delete "C₁.C₂".

Claim 1, Col. 146, line 64, delete "C₁.C₂-halalkoxy," and insert therefor --C₁.C₂-haloalkoxy--.

Claim 1, Col. 147, line 7, delete "C₁.C₂-halalkoxy,".

MAILING ADDRESS OF SENDER (Please do not use customer number

PATENT NO. 7,189,712

John L. Lemanowicz, Reg. No. 37,380
 Attorney for Patentee
 GlaxoSmithKline
 Five Moore Drive, PO Box 13398
 Research Triangle Park, NC 27709-3398

No. of additional copies

